The Blood Biomarkers of Thyroid Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Kim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol. 2020;16(1):17–29. doi:10.1038/s41574-019-0263-x31616074
   PubMed Web of Science ®Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. doi:10.1089/thy.2015.002026462967
   PubMed Web of Science ®Google Scholar
• Khatami F, Payab M, Sarvari M, et al. Oncometabolites as biomarkers in thyroid cancer: a systematic review. Cancer Manag Res. 2019;11:1829–1841. doi:10.2147/CMAR.S18866130881111
   PubMed Web of Science ®Google Scholar
• Grogan RH, Mitmaker EJ, Clark OH. The evolution of biomarkers in thyroid cancer-from mass screening to a personalized biosignature. Cancers (Basel). 2010;2(2):885–912. doi:10.3390/cancers202088524281099
   PubMedGoogle Scholar
• Melvin KEW, Miller HH, Tashjian AH. Early diagnosis of medullary carcinoma of the thyroid gland by means of calcitonin assay. N Engl J Med. 1971;285(20):1115–1120.5095737
   PubMed Web of Science ®Google Scholar
• Milhaud G, Calmette C, Taboulet J, Julienne A, Moukhtar MS. Letter: hypersecretion of calcitonin in neoplastic conditions. Lancet. 1974;1(7855):462–463. doi:10.1016/S0140-6736(74)92428-3
   PubMed Web of Science ®Google Scholar
• Alfarouk KO, Verduzco D, Rauch C, et al. Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question. Oncoscience. 2014;1(12):777–802. doi:10.18632/oncoscience.10925621294
   PubMedGoogle Scholar
• Wojtowicz W, Zabek A, Deja S, et al. Serum and urine (1)H NMR-based metabolomics in the diagnosis of selected thyroid diseases. Sci Rep. 2017;7(1):9108. doi:10.1038/s41598-017-09203-328831094
   PubMedGoogle Scholar
• Farrokhi Yekta R, Rezaei Tavirani M, Arefi Oskouie A, Mohajeri-Tehrani MR, Soroush AR, Akbarzadeh Baghban A. Serum-based metabolic alterations in patients with papillary thyroid carcinoma unveiled by non-targeted 1H-NMR metabolomics approach. Iran J Basic Med Sci. 2018;21(11):1140–1147. doi:10.22038/IJBMS.2018.30375.732330483387
   PubMed Web of Science ®Google Scholar
• Huang FQ, Li J, Jiang L, et al. Serum-plasma matched metabolomics for comprehensive characterization of benign thyroid nodule and papillary thyroid carcinoma. Int J Cancer. 2019;144(4):868–876. doi:10.1002/ijc.3192530318614
   PubMed Web of Science ®Google Scholar
• Wojakowska A, Cole LM, Chekan M, et al. Discrimination of papillary thyroid cancer from non-cancerous thyroid tissue based on lipid profiling by mass spectrometry imaging. Endokrynol Pol. 2018;69(1):2–8. doi:10.5603/EP.a2018.000329492952
   PubMed Web of Science ®Google Scholar
• Guo S, Qiu L, Wang Y, et al. Tissue imaging and serum lipidomic profiling for screening potential biomarkers of thyroid tumors by matrix-assisted laser desorption/ionization-fourier transform ion cyclotron resonance mass spectrometry. Anal Bioanal Chem. 2014;406(18):4357–4370. doi:10.1007/s00216-014-7846-024842401
   PubMed Web of Science ®Google Scholar
• Lee GB, Lee JC, Moon MH. Plasma lipid profile comparison of five different cancers by nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry. Anal Chim Acta. 2019;1063:117–126. doi:10.1016/j.aca.2019.02.02130967175
   PubMed Web of Science ®Google Scholar
• Lu ZL, Chen YJ, Jing XY, Wang NN, Zhang T, Hu CJ. Detection and identification of serum peptides biomarker in papillary thyroid cancer. Med Sci Monit. 2018;24:1581–1587. doi:10.12659/MSM.90776829549708
   PubMed Web of Science ®Google Scholar
• Evans C, Tennant S, Perros P. Serum thyroglobulin in the monitoring of differentiated thyroid cancer. Scand J Clin Lab Invest Suppl. 2016;245:S119–S123. doi:10.1080/00365513.2016.121033927542000
   PubMedGoogle Scholar
• Indrasena BS. Use of thyroglobulin as a tumour marker. World J Biol Chem. 2017;8(1):81–85. doi:10.4331/wjbc.v8.i1.8128289520
   PubMedGoogle Scholar
• Kim H, Kim YN, Kim HI, et al. Preoperative serum thyroglobulin predicts initial distant metastasis in patients with differentiated thyroid cancer. Sci Rep. 2017;7(1):16955. doi:10.1038/s41598-017-17176-629209067
   PubMedGoogle Scholar
• Kim H, Park SY, Choe J-H, et al. Preoperative serum thyroglobulin and its correlation with the burden and extent of differentiated thyroid cancer. Cancers (Basel). 2020;12(3):625. doi:10.3390/cancers12030625
   PubMed Web of Science ®Google Scholar
• Unluhizarci K, Akgun H, Oz B, Karaca Z, Tanriverdi F, Kelestimur F. Patients with papillary thyroid carcinoma associated with high stimulated serum calcitonin levels. Endocrinol Diabetes Metab Case Rep. 2017;2017.
   PubMedGoogle Scholar
• Toledo SP, Lourenco DM Jr, Santos MA, Tavares MR, Toledo RA, Correia-Deur JE. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics (Sao Paulo). 2009;64(7):699–706. doi:10.1590/S1807-5932200900070001519606248
   PubMed Web of Science ®Google Scholar
• Shen F, Cai WS, Li JL, Feng Z, Cao J, Xu B. The association between serum levels of selenium, copper, and magnesium with thyroid cancer: a meta-analysis. Biol Trace Elem Res. 2015;167(2):225–235. doi:10.1007/s12011-015-0304-925820485
   PubMed Web of Science ®Google Scholar
• de Oliveira Maia M, Batista BAM, Sousa MP, de Souza LM, Maia CSC. Selenium and thyroid cancer: a systematic review. Nutr Cancer. 2019;1–9. doi:10.1080/01635581.2019.1679194
   Web of Science ®Google Scholar
• Rayman MP. Selenium and human health. Lancet. 2012;379(9822):1256–1268. doi:10.1016/S0140-6736(11)61452-922381456
   PubMed Web of Science ®Google Scholar
• Choi YM, Kim WG, Kim TY, et al. Serum vitamin D3 levels are not associated with thyroid cancer prevalence in euthyroid subjects without autoimmune thyroid disease. Korean J Intern Med. 2017;32(1):102–108. doi:10.3904/kjim.2015.09027581957
   PubMed Web of Science ®Google Scholar
• Danilovic DL, Ferraz-de-Souza B, Fabri AW, et al. 25-hydroxyvitamin D and TSH as risk factors or prognostic markers in thyroid carcinoma. PLoS One. 2016;11(10):e0164550. doi:10.1371/journal.pone.016455027737011
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhang H, He L, et al. Potential use of 1-25-dihydroxyvitamin D in the diagnosis and treatment of papillary thyroid cancer. Med Sci Monit. 2018;24:1614–1623.29553126
   PubMed Web of Science ®Google Scholar
• Hu MJ, Niu QS, Wu HB, et al. Association of thyroid cancer risk with plasma 25-hydroxyvitamin D and vitamin D binding protein: a case-control study in China. J Endocrinol Invest. 2019:1–10.
   Web of Science ®Google Scholar
• Zhao J, Wang H, Zhang Z, et al. Vitamin D deficiency as a risk factor for thyroid cancer: a meta-analysis of case-control studies. Nutrition. 2019;57:5–11. doi:10.1016/j.nut.2018.04.01530086436
   PubMed Web of Science ®Google Scholar
• Rajoria S, Suriano R, George AL, et al. Estrogen activity as a preventive and therapeutic target in thyroid cancer. Biomed Pharmacother. 2012;66(2):151–158. doi:10.1016/j.biopha.2011.11.01022285105
   PubMed Web of Science ®Google Scholar
• Derwahl M, Nicula D. Estrogen and its role in thyroid cancer. Endocr Relat Cancer. 2014;21(5):T273–T283. doi:10.1530/ERC-14-005325052473
   PubMed Web of Science ®Google Scholar
• Jiaojiao Zheng CL, Weihui L, Wang C, Zhilong A. Quantitative assessment of preoperative serum thyrotropin level and thyroid cancer. Oncotarget. 2016;7(23):34918–34929. doi:10.18632/oncotarget.920127166998
   PubMedGoogle Scholar
• Huang H, Rusiecki J, Zhao N, et al. Thyroid-stimulating hormone, thyroid hormones, and risk of papillary thyroid cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2017;26(8):1209–1218. doi:10.1158/1055-9965.EPI-16-084528377419
   PubMed Web of Science ®Google Scholar
• Tabur S, Korkmaz H, Ozkaya M, et al. Serum calprotectin: a new potential biomarker for thyroid papillary carcinoma. Tumour Biol. 2015;36(10):7549–7556. doi:10.1007/s13277-015-3468-125916207
   PubMedGoogle Scholar
• Argyris PP, Slama ZM, Ross KF, Khammanivong A, Herzberg MC. Calprotectin and the initiation and progression of head and neck cancer. J Dent Res. 2018;97(6):674–682. doi:10.1177/002203451875633029443623
   PubMed Web of Science ®Google Scholar
• Baldane S, Ipekci SH, Sozen M, Kebapcilar L. Mean platelet volume could be a possible biomarker for papillary thyroid carcinomas. Asian Pac J Cancer Prev. 2015;16(7):2671–2674. doi:10.7314/APJCP.2015.16.7.267125854344
   PubMedGoogle Scholar
• Yu YJ, Li N, Yun ZY, et al. Preoperative mean platelet volume and platelet distribution associated with thyroid cancer. Neoplasma. 2017;64(4):594–598. doi:10.4149/neo_2017_41428485166
   PubMed Web of Science ®Google Scholar
• Dincel O, Bayraktar C. Evaluation of platelet indices as a useful marker in papillary thyroid carcinoma. Bratisl Lek Listy. 2017;118(3):153–155. doi:10.4149/BLL_2017_03028319410
   PubMed Web of Science ®Google Scholar
• Cai X, Janku F, Zhan Q, Fan J-B. Accessing genetic information with liquid biopsies. Trends Genet. 2015;31(10):564–575. doi:10.1016/j.tig.2015.06.00126450339
   PubMed Web of Science ®Google Scholar
• Caglar O, Cilgin B, Eroglu M, Cayir A. Evaluation of circulating cell free DNA in plasma as a biomarker of different thyroid diseases. Braz J Otorhinolaryngol. 2019.
   PubMed Web of Science ®Google Scholar
• Perdas E, Stawski R, Kaczka K, Nowak D, Zubrzycka M. Altered levels of circulating nuclear and mitochondrial DNA in patients with papillary thyroid cancer. Sci Rep. 2019;9(1):14438. doi:10.1038/s41598-019-51000-731594998
   PubMedGoogle Scholar
• Sedaghati M, Kebebew E. Long noncoding RNAs in thyroid cancer. Curr Opin Endocrinol Diabetes Obes. 2019;26(5):275–281. doi:10.1097/MED.000000000000049731385810
   PubMedGoogle Scholar
• Yu S, Liu Y, Wang J, et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97(6):2084–2092. doi:10.1210/jc.2011-305922472564
   PubMed Web of Science ®Google Scholar
• Lee JC, Zhao JT, Clifton-Bligh RJ, et al. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer. 2013;119(24):4358–4365. doi:10.1002/cncr.2825424301304
   PubMed Web of Science ®Google Scholar
• Graham ME, Hart RD, Douglas S, et al. Serum microRNA profiling to distinguish papillary thyroid cancer from benign thyroid masses. J Otolaryngol Head Neck Surg. 2015;44(1):33. doi:10.1186/s40463-015-0083-526341226
   PubMedGoogle Scholar
• Rosignolo F, Sponziello M, Giacomelli L, et al. Identification of thyroid-associated serum microRNA profiles and their potential use in thyroid cancer follow-up. J Endocr Soc. 2017;1(1):3–13. doi:10.1210/js.2016-103229264441
   PubMedGoogle Scholar
• Rezaei M, Khamaneh AM, Zarghami N, Vosoughi A, Hashemzadeh S. Evaluating pre- and post-operation plasma miRNAs of papillary thyroid carcinoma (PTC) patients in comparison to benign nodules. BMC Cancer. 2019;19(1):690. doi:10.1186/s12885-019-5849-031307429
   PubMed Web of Science ®Google Scholar
• Zhang A, Wang C, Lu H, et al. Altered serum MicroRNA profile may serve as an auxiliary tool for discriminating aggressive thyroid carcinoma from nonaggressive thyroid cancer and benign thyroid nodules. Dis Markers. 2019;2019:3717683. doi:10.1155/2019/371768331636734
   PubMed Web of Science ®Google Scholar
• Chuanyou C, Quansheng W, Yuzhong Q, Jianing L, Bo L, Bin L. Clinical value of combination detection of HMGB-1 and TSGF for diagnosis of thyroid cancer. Chin J Gen Surg. 2012;21(05):536–539.
   Google Scholar
• Mardente S, Mari E, Massimi I, et al. HMGB1-induced cross talk between PTEN and miRs 221/222 in thyroid cancer. Biomed Res Int. 2015;2015:512027. doi:10.1155/2015/51202726106610
   PubMed Web of Science ®Google Scholar
• Choi YW, Kim YH, Lee J, Soh EY, Park TJ, Kim JH. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma. Hum Pathol. 2015;46(10):1557–1565. doi:10.1016/j.humpath.2015.06.01826297257
   PubMed Web of Science ®Google Scholar
• Kuzu F, Arpaci D, Unal M, et al. Midkine: a novel biomarker to predict malignancy in patients with nodular thyroid disease. Int J Endocrinol. 2016;2016:6035024. doi:10.1155/2016/603502427446208
   PubMed Web of Science ®Google Scholar
• Meng Z, Tan J, Zhang G, et al. Evaluation of serum midkine as a biomarker in differentiated thyroid cancer. Life Sci. 2015;130:18–24. doi:10.1016/j.lfs.2015.02.02825817231
   PubMed Web of Science ®Google Scholar
• Li N, Zhang C, Meng Z, et al. Changes of serum midkine as a dynamic prognostic factor to monitor disease status in papillary thyroid cancer. Medicine (Baltimore). 2018;97(36):e12242. doi:10.1097/MD.000000000001224230200153
   PubMed Web of Science ®Google Scholar
• Martins MB, Marcello MA, Batista FA, et al. Serum interleukin measurement may help identify thyroid cancer patients with active disease. Clin Biochem. 2018;52:1–7. doi:10.1016/j.clinbiochem.2017.10.00328987791
   PubMed Web of Science ®Google Scholar
• Shi Y, Su C, Hu H, et al. Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma. PLoS One. 2018;13(6):e0198896. doi:10.1371/journal.pone.019889629949618
   PubMed Web of Science ®Google Scholar
• Zhang WJ, Song B, Yang T. MMP-2, MMP-9, TIMP-1, and TIMP-2 in the peripheral blood of patients with differentiated thyroid carcinoma. Cancer Manag Res. 2019;11:10675–10681. doi:10.2147/CMAR.S23377631920377
   PubMedGoogle Scholar
• Hu Z, Zhao P, Zhang K, Zang L, Liao H, Ma W. Evaluation of serum vascular adhesion protein-1 as a potential biomarker in thyroid cancer. Int J Endocrinol. 2016;2016:6312529. doi:10.1155/2016/631252927446209
   PubMed Web of Science ®Google Scholar
• Baki A, Tosun İ, Yıldız M. Can VAP-1 protein be used as a biomarker in thyroid cancer? Istanb Med J. 2019;20(6):335–340. doi:10.4274/imj.galenos.2019.26817
   Web of Science ®Google Scholar
• Htwe TT, Karim N, Wong J, Jahanfar S, Mansur MA. Differential expression of galectin-3 in advancing thyroid cancer cells: a clue toward understanding tumour progression and metastasis. Singapore Med J. 2010;51(11):856–859.21140111
   PubMed Web of Science ®Google Scholar
• Saggiorato E, Cappia S, De Giuli P, et al. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab. 2001;86(11):5152–5158. doi:10.1210/jcem.86.11.804311701669
   PubMed Web of Science ®Google Scholar
• Arcolia V, Journe F, Wattier A, et al. Galectin-1 is a diagnostic marker involved in thyroid cancer progression. Int J Oncol. 2017;51(3):760–770. doi:10.3892/ijo.2017.406528677745
   PubMed Web of Science ®Google Scholar
• Sven Saussez DG, Chantrain G, Pattou F, et al. Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid. 2008;18(7):705–712.18630998
   PubMed Web of Science ®Google Scholar
• Yilmaz E, Karsidag T, Tatar C, Tuzun S. Serum galectin-3: diagnostic value for papillary thyroid carcinoma. Ulus Cerrahi Derg. 2015;31(4):192–196. doi:10.5152/UCD.2015.292826668525
   PubMedGoogle Scholar
• Adil A, Mohammed A, Abdulhafidh A. Beta-2-microglobulin as a marker in patients with thyroid cancer. Iraqi Acad Sci J. 2019;18(1):18–22.
   Google Scholar
• Lee J, Park HL, Jeong C-W, et al. CYFRA 21-1 in lymph node fine needle aspiration washout improves diagnostic accuracy for metastatic lymph nodes of differentiated thyroid cancer. Cancers (Basel). 2019;11(4):487. doi:10.3390/cancers11040487
   PubMed Web of Science ®Google Scholar
• Liu L, Xie W, Xue P, Wei Z, Liang X, Chen N. Diagnostic accuracy and prognostic applications of CYFRA 21-1 in head and neck cancer: a systematic review and meta-analysis. PLoS One. 2019;14(5):e0216561. doi:10.1371/journal.pone.021656131071161
   PubMed Web of Science ®Google Scholar
• Giovanella L, Imperiali M, Trimboli P. Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer. Sci Rep. 2017;7(1):7359. doi:10.1038/s41598-017-07915-028779086
   PubMedGoogle Scholar
• Gambardella C, Polistena A, Sanguinetti A, et al. Unintentional recurrent laryngeal nerve injuries following thyroidectomy: is it the surgeon who pays the bill? Int J Surg. 2017;41(Suppl 1):S55–S59. doi:10.1016/j.ijsu.2017.01.11228506414
   PubMedGoogle Scholar
• Conzo G, Polistena A, Calo PG, et al. Efficacy of combined treatment for anaplastic thyroid carcinoma: results of a multinstitutional retrospective analysis. Int J Surg. 2014;12(Suppl 1):S178–S182. doi:10.1016/j.ijsu.2014.05.01524866070
   PubMedGoogle Scholar